Seroquel (quetiapine fumarate) - Apr 8, 2004

April 8, 2004

Audience: Neuropsychiatric healthcare professionals

FDA and AstraZeneca notified healthcare professionals of revision to the WARNINGS section of labeling, describing the increased risk of hyperglycemia and diabetes in patients taking Seroquel. FDA has asked all manufacturers of atypical antipsychotic medications, including AstraZeneca, to add this Warning statement to labeling.

View comments

Hide
(web2)